Shamrock Asset Management LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,536 shares of the biopharmaceutical company’s stock, valued at approximately $512,000.

Several other large investors also recently made changes to their positions in GILD. Keel Point LLC increased its stake in shares of Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 11 shares during the last quarter. Westover Capital Advisors LLC increased its stake in shares of Gilead Sciences by 0.8% in the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock valued at $378,000 after buying an additional 46 shares during the last quarter. Abner Herrman & Brock LLC increased its stake in shares of Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 50 shares during the last quarter. ARS Investment Partners LLC increased its stake in shares of Gilead Sciences by 0.9% in the first quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock valued at $381,000 after buying an additional 50 shares during the last quarter. Finally, Blue Fin Capital Inc. increased its stake in shares of Gilead Sciences by 0.8% in the first quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 55 shares during the last quarter. Institutional investors and hedge funds own 74.02% of the company’s stock.

Shares of Gilead Sciences, Inc. (GILD) traded up 0.86% on Wednesday, hitting $73.75. The stock had a trading volume of 1,856,800 shares. The firm has a 50 day moving average price of $72.48 and a 200 day moving average price of $68.76. The company has a market capitalization of $96.31 billion, a P/E ratio of 8.01 and a beta of 1.21. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $82.10.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the business posted $3.08 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.84%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is presently 22.58%.

WARNING: “Shamrock Asset Management LLC Buys Shares of 7,536 Gilead Sciences, Inc. (GILD)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/shamrock-asset-management-llc-buys-shares-of-7536-gilead-sciences-inc-gild/1495892.html.

Several equities research analysts have issued reports on the company. Jefferies Group LLC restated a “hold” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 11th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price objective on the stock. in a report on Tuesday, April 25th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 3rd. BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Finally, Barclays PLC restated an “overweight” rating and set a $85.00 price objective on shares of Gilead Sciences in a report on Wednesday, May 3rd. Twelve analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $80.31.

In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders have sold a total of 206,666 shares of company stock worth $15,223,184 in the last ninety days. 1.30% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.